BMS 509744, is a potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitor. It reduces HIV infection of primary CD4+ T cells, and in vitro.
ChEBI: N-[5-[[5-[(4-acetyl-1-piperazinyl)-oxomethyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]-4-[(3,3-dimethylbutan-2-ylamino)methyl]benzamide is a member of benzamides.
Cell permeable: yes', 'Primary Target
ITK', 'Target IC50: 19 nM for ITK
BMS-509744 and BMS-488516 suppress the production of IL-2 induced by anti-T-cell receptor antibody administered to mice. BMS-509744 exhibits a 50% inhibitory capacity when dosed at 50 mg/kg, irrespective of the amount of induction antibody. BMS-509744 also significantly diminishes lung inflammation in a mouse model of ovalbumin-induced allergy/asthma[1].
